Antibody specifically binding to ErbB3 and use thereof

1. An antibody or an antigen-binding fragment thereof that specifically binds to ErbB3, comprising:

heavy chain complementarity determining regions (CDR-Hs) and light chain complementarity determining regions (CDR-Ls), wherein the antibody is selected from the group consisting of:

(1) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 69, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(2) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 70, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 95;

(3) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 71, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(4) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 72, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(5) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 73, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(6) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 71, a CDR-H3 having the sequence of SEQ ID NO: 79, a CDR-L1 having the sequence of SEQ ID NO: 87, a CDR-L2 having the sequence of SEQ ID NO: 89, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(7) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 69, a CDR-H3 having the sequence of SEQ ID NO: 79, a CDR-L1 having the sequence of SEQ ID NO: 87, a CDR-L2 having the sequence of SEQ ID NO: 90, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(8) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 69, a CDR-H3 having the sequence of SEQ ID NO: 79, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(9) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 69, a CDR-H3 having the sequence of SEQ ID NO: 79, a CDR-L1 having the sequence of SEQ ID NO: 87, a CDR-L2 having the sequence of SEQ ID NO: 89, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(10) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 70, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 96;

(11) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 70, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 97;

(12) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 74, a CDR-H3 having the sequence of SEQ ID NO: 79, a CDR-L1 having the sequence of SEQ ID NO: 87, a CDR-L2 having the sequence of SEQ ID NO: 89, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(13) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 75, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(14) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 69, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 98;

(15) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 71, a CDR-H3 having the sequence of SEQ ID NO: 80, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 91, and a CDR-L3 having the sequence of SEQ ID NO: 94;

(16) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 102, a CDR-H3 having the sequence of SEQ ID NO: 78, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 88, and a CDR-L3 having the sequence of SEQ ID NO: 99;

(17) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 76, a CDR-H3 having the sequence of SEQ ID NO: 81, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 92, and a CDR-L3 having the sequence of SEQ ID NO: 100;

(18) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 62, a CDR-H2 having the sequence of SEQ ID NO: 76, a CDR-H3 having the sequence of SEQ ID NO: 81, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 92, and a CDR-L3 having the sequence of SEQ ID NO: 100;

(19) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 63, a CDR-H2 having the sequence of SEQ ID NO: 76, a CDR-H3 having the sequence of SEQ ID NO: 81, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 92, and a CDR-L3 having the sequence of SEQ ID NO: 100;

(20) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 64, a CDR-H2 having the sequence of SEQ ID NO: 76, a CDR-H3 having the sequence of SEQ ID NO: 81, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 92, and a CDR-L3 having the sequence of SEQ ID NO: 100;

(21) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 65, a CDR-H2 having the sequence of SEQ ID NO: 76, a CDR-H3 having the sequence of SEQ ID NO: 81, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 92, and a CDR-L3 having the sequence of SEQ ID NO: 100;

(22) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 66, a CDR-H2 having the sequence of SEQ ID NO: 76, a CDR-H3 having the sequence of SEQ ID NO: 81, a CDR-L1 having the sequence of SEQ ID NO: 86, a CDR-L2 having the sequence of SEQ ID NO: 92, and a CDR-L3 having the sequence of SEQ ID NO: 100;

(23) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 77, a CDR-H3 having the sequence of SEQ ID NO: 82, a CDR-L1 having the sequence of SEQ ID NO: 103, a CDR-L2 having the sequence of SEQ ID NO: 93, and a CDR-L3 having the sequence of SEQ ID NO: 101;

(24) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 77, a CDR-H3 having the sequence of SEQ ID NO: 83, a CDR-L1 having the sequence of SEQ ID NO: 103, a CDR-L2 having the sequence of SEQ ID NO: 93, and a CDR-L3 having the sequence of SEQ ID NO: 101;

(25) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 77, a CDR-H3 having the sequence of SEQ ID NO: 84, a CDR-L1 having the sequence of SEQ ID NO: 103, a CDR-L2 having the sequence of SEQ ID NO: 93, and a CDR-L3 having the sequence of SEQ ID NO: 101;

(26) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 67, a CDR-H2 having the sequence of SEQ ID NO: 77, a CDR-H3 having the sequence of SEQ ID NO: 84, a CDR-L1 having the sequence of SEQ ID NO: 103, a CDR-L2 having the sequence of SEQ ID NO: 93, and a CDR-L3 having the sequence of SEQ ID NO: 101;

(27) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 68, a CDR-H2 having the sequence of SEQ ID NO: 77, a CDR-H3 having the sequence of SEQ ID NO: 84, a CDR-L1 having the sequence of SEQ ID NO: 103, a CDR-L2 having the sequence of SEQ ID NO: 93, and a CDR-L3 having the sequence of SEQ ID NO: 101,

(28) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 61, a CDR-H2 having the sequence of SEQ ID NO: 77, a CDR-H3 having the sequence of SEQ ID NO: 85, a CDR-L1 having the sequence of SEQ ID NO: 103, a CDR-L2 having the sequence of SEQ ID NO: 93, and a CDR-L3 having the sequence of SEQ ID NO: 101,

(29) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 67, a CDR-H2 having the sequence of SEQ ID NO: 77, a CDR-H3 having the sequence of SEQ ID NO: 85, a CDR-L1 having the sequence of SEQ ID NO: 103, a CDR-L2 having the sequence of SEQ ID NO: 93, and a CDR-L3 having the sequence of SEQ ID NO: 101, and

(30) an antibody comprising a CDR-H1 having the sequence of SEQ ID NO: 68, a CDR-H2 having the sequence of SEQ ID NO: 77, a CDR-H3 having the sequence of SEQ ID NO: 85, a CDR-L1 having the sequence of SEQ ID NO: 103, a CDR-L2 having the sequence of SEQ ID NO: 93, and a CDR-L3 having the sequence of SEQ ID NO: 101.

2. The antibody or the antigen-binding fragment of claim 1 , wherein the heavy chain variable region further comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 30.

3. The antibody or the antigen-binding fragment of claim 1 , wherein the light chain variable region further comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 31 to 60.

4. The antibody or the antigen-binding fragment of claim 1 , wherein the antibody or the antigen-binding fragment inhibits (a) binding of ErbB3 protein to a material specifically binding thereto, (b) dimerization of ErbB1 protein and ErbB3 protein, (c) dimerization of ErbB2 protein and ErbB3 protein, (d) phosphorylation of ErbB3 or Akt, or (e) a combination thereof.

5. The antibody or the antigen-binding fragment of claim 4 , wherein the material specifically binding to the ErbB3 protein is heregulin (HRG).

6. The antibody or the antigen-binding fragment of claim 1 ,

wherein the antibody is IgA, IgD, IgE, IgG, or IgM;

or

wherein the antigen-binding fragment is scFv, (scFv)2, Fv, Fab, Fab′, F(ab′)2, or a combination thereof; or

wherein the antibody or the antigen-binding fragment thereof is modified by conjugation or binding, glycosylation, tag attachment, or a combination thereof.

7. A pharmaceutical composition for treatment of a disease related to activation or overexpression of ErbB3 protein, the pharmaceutical composition comprising the antibody or the antigen-binding fragment of claim 1 .

8. The pharmaceutical composition of claim 7 , wherein the disease related to activation or overexpression of the ErbB3 protein is cancer.

9. The pharmaceutical composition of claim 8 , wherein the cancer is selected from the group consisting of breast cancer, skin cancer, head and neck cancer, pancreatic cancer, lung cancer, colon cancer, colorectal cancer, gastric cancer, ovarian cancer, prostate cancer, bladder cancer, uterine cancer, liver cancer, kidney cancer, clear cell sarcoma, melanoma, cerebrospinal tumors, brain cancer, thymoma, mesothelioma, esophageal cancer, biliary tract cancer, testicular cancer, germinal cancer, thyroid cancer, parathyroid cancer, cervical cancer, endometrial cancer, lymphoma, myelodysplastic syndromes (MDS), myelofibrosis, acute leukemia, chronic leukemia, multiple myeloma, Hodgkin's disease, endocrine cancer, and sarcoma.

10. The pharmaceutical composition of claim 7 , further comprising an anti-cancer drug.

11. The pharmaceutical composition of claim 10 , wherein the anti-cancer drug is Cetuximab, Panitumumab, Erlotinib, Gefitinib, Trastuzumab, T-DM1, Pertuzumab, Lapatinib, Paclitaxel, Tamoxifen, Cisplatin, anti-CTLA-4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, 5-fluorouracil (5FU), Gemcitabine, or a combination thereof.

12. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition further comprises a single composition or separate compositions.

13. A method of treatment of a disease related to activation or overexpression of ErbB3 protein in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 1 to the individual.

14. The method of claim 13 , further comprising administering an anti-cancer drug to the individual.

15. The method of claim 14 , wherein the anti-cancer drug is administered at the same time with, separately from, or sequentially with the antibody or the antigen-binding fragment of claim 1 .

16. The method of claim 14 , wherein the antibody, the antigen-binding fragment thereof, the anti-cancer drug, or a combination thereof are administered to the individual by oral, intravenous, intramuscular, transdermal, mucosal, intranasal, intratracheal, subcutaneous administration and a combination thereof.

17. The method of claim 14 , wherein the antibody, the antigen-binding fragment thereof, the anti-cancer drug, or a combination thereof are administered systemically or locally.

18. A method of treatment of cancer drug resistance in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 1 to the individual.

19. A pharmaceutical composition for treatment of a disease related to activation or overexpression of ErbB3 protein, the pharmaceutical composition comprising the antibody or the antigen-binding fragment of claim 2 .

20. A pharmaceutical composition for treatment of a disease related to activation or overexpression of ErbB3 protein, the pharmaceutical composition comprising the antibody or the antigen-binding fragment of claim 3 .

21. A pharmaceutical composition for treatment of a disease related to activation or overexpression of ErbB3 protein, the pharmaceutical composition comprising the antibody or the antigen-binding fragment of claim 4 .

22. A pharmaceutical composition for treatment of a disease related to activation or overexpression of ErbB3 protein, the pharmaceutical composition comprising the antibody or the antigen-binding fragment of claim 5 .

23. A pharmaceutical composition for treatment of a disease related to activation or overexpression of ErbB3 protein, the pharmaceutical composition comprising the antibody or the antigen-binding fragment of claim 6 .

24. A method of treatment of a disease related to activation or overexpression of ErbB3 protein in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 2 to the individual.

25. A method of treatment of a disease related to activation or overexpression of ErbB3 protein in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 3 to the individual.

26. A method of treatment of a disease related to activation or overexpression of ErbB3 protein in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 4 to the individual.

27. A method of treatment of a disease related to activation or overexpression of ErbB3 protein in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 5 to the individual.

28. A method of treatment of a disease related to activation or overexpression of ErbB3 protein in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 6 to the individual.

29. A method treatment of cancer drug resistance in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 2 to the individual.

30. A method treatment of cancer drug resistance in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 3 to the individual.

31. A method treatment of cancer drug resistance in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 4 to the individual.

32. A method of treatment of cancer drug resistance in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 5 to the individual.

33. A method of treatment of cancer drug resistance in an individual, the method comprising administering the antibody or the antigen-binding fragment of claim 6 to the individual.